Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus azacitidine for molecular relapse/progression in adult NPM1-mutated acute myeloid leukemia
2021-002361-17Phase 2Active
- Sponsor
- GIMEMA
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Patients without overt relapse at 6 months or by stem cell transplant. Started Aug 2021; status: active.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-002361-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002361-17.